

Wearable Injectors Market by Product (On-body, Off-body), Technology (Spring, Motor Driven, Rotary Pump), Usage (Disposable, Reusable), Delivery Method (Bolus, Programmed Infusion), Therapeutic Application (Diabetes, Oncology), End User - Forecast to 2030

Market Report | 2025-09-09 | 452 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The wearable injectors market is projected to grow from USD 11.33 billion in 2025 to USD 18.91 billion by 2030, at a CAGR of 10.8% during the forecast period. The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has created a demand for the precise, controlled, and continuous delivery of pharmacological therapies, significantly driving the growth of wearable injector technologies. Moreover, advancements in device engineering, increased spending on research and development, and the integration of the Internet of Things (IoT) and remote monitoring are enhancing patient safety and improving the efficiency of drug administration. Additionally, the shift towards home-based healthcare solutions, as opposed to traditional inpatient settings, is generating further demand for these advanced delivery systems. Furthermore, stringent regulatory frameworks surrounding wearable injectors are promoting the development of safer and more reliable systems, thereby reinforcing market expansion.

<https://www.marketsandmarkets.com/Images/wearable-injector-market-Overview.webp>

"The spring-based technology segment accounted for the largest share of the wearable injectors market, by technology, in 2024." By technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. Spring-based wearable injectors currently hold the largest share of the market because of their simple design, cost-effectiveness, and reliability. These devices utilize a mechanical spring mechanism to deliver drugs subcutaneously, which eliminates the need for complex motors or batteries. Their ease of manufacturing and reduced risk of mechanical failure make

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

them a preferred choice for both manufacturers and patients. Furthermore, spring-based injectors are widely used in the management of chronic diseases, particularly in oncology and diabetes, where frequent and controlled dosing is crucial. The widespread adoption of these injectors in both developed and developing markets is expected to sustain their dominance through 2030.

"The disposable wearable injectors segment is expected to dominate the market, by usage, during the forecast period." The wearable injectors market is divided into two categories based on usage: disposable and reusable injectors. The disposable wearable injectors segment is expected to dominate the usage category during the forecast period. These devices are designed for single use, which helps reduce the risk of contamination, improve safety, and enhance patient convenience. They are especially favored in situations that require strict sterility, such as oncology treatments and the administration of biologic drugs. Additionally, the growing prevalence of biologics and personalized therapies, which often necessitate self-administration, has increased the demand for user-friendly, ready-to-use injectors. The absence of the need for maintenance, calibration, or cleaning further makes disposable injectors appealing to both patients and healthcare providers, solidifying their position as market leaders.

"The North American region is expected to capture the largest share during the forecast period." North America continues to be the dominant and fastest-growing region in the wearable injectors market. This growth is primarily driven by a robust healthcare infrastructure, high healthcare expenditures, and the early adoption of advanced drug delivery technologies. The US and Canada lead the way, with a significant portion of the population suffering from chronic diseases such as diabetes, cancer, and autoimmune disorders-conditions that require regular and precise medication administration. The region also benefits from a strong presence of key market players and continuous innovation in biologics and personalized medicine, both of which demand sophisticated delivery solutions like wearable injectors. Additionally, the increasing trend toward outpatient care and home-based treatment, along with favorable reimbursement policies and strong regulatory support, further accelerates market growth. Technological advancements, including the integration of digital health features and connectivity in wearable injectors, are improving treatment adherence, patient monitoring, and clinical outcomes. These developments align well with North America's focus on value-based care, further solidifying the region's leadership in the global wearable injectors market.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

- By Company Type: Hospitals (45%), Home Care Settings (30%), Ambulatory Surgery Centers/Specialty Infusion Centers (20%), and Other End Users (5%)
- By Designation: Healthcare Professionals (35%), Department Heads (27%), Procurement Heads (22%), and Other Designations (16%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the wearable injectors market based on product, technology, usage, delivery method, therapeutic application, manufacturing type, end user, and region. It also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the market's opportunities and challenges and provides details of the competitive landscape for market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established companies and new or smaller firms understand market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

- Analysis of key drivers (increased shift to home care settings, rising prevalence of chronic diseases, and rising aging population), restraints (high cost of wearable injectors), opportunities (high growth potential in emerging economies), and challenges (lack of training and education for using wearable injectors) influencing the growth of the wearable injectors market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the wearable injectors market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of wearable injectors across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the wearable injectors market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market. The wearable injectors market is projected to grow from USD 11.33 billion in 2025 to USD 18.91 billion by 2030, at a CAGR of 10.8% during the forecast period. The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has created a demand for the precise, controlled, and continuous delivery of pharmacological therapies, significantly driving the growth of wearable injector technologies. Moreover, advancements in device engineering, increased spending on research and development, and the integration of the Internet of Things (IoT) and remote monitoring are enhancing patient safety and improving the efficiency of drug administration. Additionally, the shift towards home-based healthcare solutions, as opposed to traditional inpatient settings, is generating further demand for these advanced delivery systems. Furthermore, stringent regulatory frameworks surrounding wearable injectors are promoting the development of safer and more reliable systems, thereby reinforcing market expansion.

<https://www.marketsandmarkets.com/Images/wearable-injector-market-Overview.webp>

"The spring-based technology segment accounted for the largest share of the wearable injectors market, by technology, in 2024." By technology, the wearable injectors market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and other technologies. Spring-based wearable injectors currently hold the largest share of the market because of their simple design, cost-effectiveness, and reliability. These devices utilize a mechanical spring mechanism to deliver drugs subcutaneously, which eliminates the need for complex motors or batteries. Their ease of manufacturing and reduced risk of mechanical failure make them a preferred choice for both manufacturers and patients. Furthermore, spring-based injectors are widely used in the management of chronic diseases, particularly in oncology and diabetes, where frequent and controlled dosing is crucial. The widespread adoption of these injectors in both developed and developing markets is expected to sustain their dominance through 2030.

"The disposable wearable injectors segment is expected to dominate the market, by usage, during the forecast period." The wearable injectors market is divided into two categories based on usage: disposable and reusable injectors. The disposable wearable injectors segment is expected to dominate the usage category during the forecast period. These devices are designed for single use, which helps reduce the risk of contamination, improve safety, and enhance patient convenience. They are especially favored in situations that require strict sterility, such as oncology treatments and the administration of biologic drugs. Additionally, the growing prevalence of biologics and personalized therapies, which often necessitate self-administration, has increased the demand for user-friendly, ready-to-use injectors. The absence of the need for maintenance, calibration, or cleaning

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

further makes disposable injectors appealing to both patients and healthcare providers, solidifying their position as market leaders.

"The North American region is expected to capture the largest share during the forecast period."

North America continues to be the dominant and fastest-growing region in the wearable injectors market. This growth is primarily driven by a robust healthcare infrastructure, high healthcare expenditures, and the early adoption of advanced drug delivery technologies. The US and Canada lead the way, with a significant portion of the population suffering from chronic diseases such as diabetes, cancer, and autoimmune disorders-conditions that require regular and precise medication administration. The region also benefits from a strong presence of key market players and continuous innovation in biologics and personalized medicine, both of which demand sophisticated delivery solutions like wearable injectors. Additionally, the increasing trend toward outpatient care and home-based treatment, along with favorable reimbursement policies and strong regulatory support, further accelerates market growth. Technological advancements, including the integration of digital health features and connectivity in wearable injectors, are improving treatment adherence, patient monitoring, and clinical outcomes. These developments align well with North America's focus on value-based care, further solidifying the region's leadership in the global wearable injectors market.

Breakdown of supply-side primary interviews:

- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

- By Company Type: Hospitals (45%), Home Care Settings (30%), Ambulatory Surgery Centers/Specialty Infusion Centers (20%), and Other End Users (5%)
- By Designation: Healthcare Professionals (35%), Department Heads (27%), Procurement Heads (22%), and Other Designations (16%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the wearable injectors market based on product, technology, usage, delivery method, therapeutic application, manufacturing type, end user, and region. It also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the market's opportunities and challenges and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established companies and new or smaller firms understand market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

- Analysis of key drivers (increased shift to home care settings, rising prevalence of chronic diseases, and rising aging population), restraints (high cost of wearable injectors), opportunities (high growth potential in emerging economies), and challenges (lack of training and education for using wearable injectors) influencing the growth of the wearable injectors market.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the wearable injectors market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

types of wearable injectors across regions.

-□Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the wearable injectors market.

-□Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.

Table of Contents:

1	INTRODUCTION	36
1.1	STUDY OBJECTIVES	36
1.2	MARKET DEFINITION	36
1.3	MARKET SCOPE	36
1.3.1	MARKET SEGMENTATION	37
1.3.2	YEARS CONSIDERED	38
1.4	INCLUSIONS AND EXCLUSIONS	38
1.4.1	CURRENCY CONSIDERED	39
1.5	STAKEHOLDERS	39
1.6	LIMITATIONS	39
1.7	SUMMARY OF CHANGES	40
2	RESEARCH METHODOLOGY	42
2.1	RESEARCH DATA	42
2.1.1	SECONDARY DATA	43
2.1.1.1	Key secondary sources	44
2.1.2	PRIMARY DATA	45
2.1.2.1	Primary sources	45
2.1.2.2	Key data from primary sources	46
2.1.2.3	Key industry insights	47
2.1.2.4	Breakdown of primary interviews	47
2.2	MARKET SIZE ESTIMATION	48
2.2.1	APPROACH 1: SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)	48
2.2.2	APPROACH 2: COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS	51
2.2.3	APPROACH 3: BOTTOM-UP APPROACH	51
2.2.4	APPROACH 4: TOP-DOWN APPROACH	51
2.2.5	APPROACH 5: DEMAND-SIDE APPROACH	52
2.2.6	APPROACH 6: VOLUME DATA ANALYSIS	53
2.2.7	APPROACH 7: ADJACENT MARKET APPROACH	53
2.2.7.1	Injectable drug delivery market	53
2.2.7.2	Pharmaceutical drug delivery market	54
2.3	DATA TRIANGULATION	57
2.4	MARKET SHARE ESTIMATION	57
2.5	RESEARCH ASSUMPTIONS	58
2.5.1	GROWTH RATE ASSUMPTIONS	58
2.6	RISK ASSESSMENT	59
2.7	RESEARCH LIMITATIONS	59
2.7.1	METHODOLOGY-RELATED LIMITATIONS	59
2.7.2	SCOPE-RELATED LIMITATIONS	59
3	EXECUTIVE SUMMARY	60
4	PREMIUM INSIGHTS	68

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.1	ATTRACTIVE OPPORTUNITIES IN WEARABLE INJECTORS MARKET	68
4.2	ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY APPLICATION AND COUNTRY	69
4.3	WEARABLE INJECTORS MARKET: REGIONAL MIX	70
4.4	WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	71
4.5	WEARABLE INJECTORS MARKET: DEVELOPED VS. DEVELOPING MARKETS	72
5	MARKET OVERVIEW	73
5.1	INTRODUCTION	73
5.2	MARKET DYNAMICS	74
5.2.1	DRIVERS	74
5.2.1.1	Rising burden of chronic diseases and aging population	74
5.2.1.2	Growing preference for home healthcare and self-administration	77
5.2.1.3	Increased number of R&D activities and strategic partnerships	77
5.2.1.4	Use of artificial intelligence in diabetes management devices	79
5.2.2	RESTRAINTS	79
5.2.2.1	High cost of wearable injectors and lack of reimbursement plans in emerging economies	79
5.2.2.2	Stringent regulatory requirements for new product approval	80
5.2.3	OPPORTUNITIES	81
5.2.3.1	Significant growth potential in emerging economies	81
5.2.3.2	Integration with digital health & remote monitoring	82
5.2.4	CHALLENGES	82
5.2.4.1	Lack of training and education for using wearable injectors	82
5.3	INDUSTRY TRENDS	83
5.3.1	INTEGRATION OF SMART CONNECTIVITY & DIGITAL HEALTH FEATURES	83
5.3.2	LARGE-VOLUME ON-BODY BIOLOGICS INJECTORS	84
5.4	TECHNOLOGY ANALYSIS	85
5.4.1	KEY TECHNOLOGIES	85
5.4.1.1	Micro-MEMS and Bio-MEMS in wearable injectors	85
5.4.1.2	Electromechanical drive systems (motorized pumps)	85
5.4.1.3	Sensor-integrated closed-loop wearable injector	86
5.4.2	COMPLEMENTARY TECHNOLOGIES	86
5.4.2.1	Smartphone and app interfaces	86
5.4.2.2	IoT and smart analytics in wearable injectors	87
5.4.3	ADJACENT TECHNOLOGIES	88
5.4.3.1	Electrochemical aptamer biosensors	88
5.4.3.2	Telemedicine platforms	88
?		
5.5	PORTER'S FIVE FORCES ANALYSIS	89
5.5.1	THREAT OF NEW ENTRANTS	90
5.5.2	THREAT OF SUBSTITUTES	90
5.5.3	BARGAINING POWER OF SUPPLIERS	90
5.5.4	BARGAINING POWER OF BUYERS	91
5.5.5	INTENSITY OF COMPETITIVE RIVALRY	91
5.6	PIPELINE ANALYSIS	91
5.7	REGULATORY LANDSCAPE	92
5.7.1	REGULATORY ANALYSIS	92
5.7.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	94
5.8	PATENT ANALYSIS	96

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8.1	PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS	96
5.8.2	INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS	97
5.9	TRADE ANALYSIS	99
5.9.1	TRADE DATA FOR HS CODE 901890	99
5.9.1.1	Import data for HS Code 901890	99
5.9.1.2	Export data for HS Code 901890	100
5.10	PRICING ANALYSIS	100
5.10.1	AVERAGE SELLING PRICE, BY KEY PLAYER	100
5.10.1.1	Average selling price trend among key players	101
5.10.2	AVERAGE SELLING PRICE, BY REGION	102
5.10.2.1	Average selling price trend of on-body wearable injector, by region	103
5.10.2.2	Average selling price trend of off-body wearable injector, by region	103
5.11	REIMBURSEMENT ANALYSIS	103
5.12	KEY CONFERENCES & EVENTS, 2025-2026	105
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	106
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS (DEVICES)	106
5.13.2	KEY STAKEHOLDERS IN BUYING PROCESS (FORMULATIONS)	107
5.13.3	BUYING CRITERIA	107
5.14	UNMET NEEDS/END-USER EXPECTATIONS	109
5.15	IMPACT OF AI ON WEARABLE INJECTORS MARKET	109
5.15.1	INTRODUCTION	109
5.15.2	MARKET POTENTIAL IN WEARABLE INJECTORS ECOSYSTEM	110
5.15.3	AI USE CASES	110
5.15.4	KEY COMPANIES IMPLEMENTING AI IN WEARABLE INJECTORS	111
5.15.5	FUTURE OF GEN AI IN WEARABLE INJECTORS ECOSYSTEM	111
5.16	ECOSYSTEM ANALYSIS	112
5.16.1	WEARABLE INJECTOR PROVIDERS	112
5.16.2	END USERS	114
5.16.3	REGULATORY BODIES	114
5.17	VALUE CHAIN ANALYSIS	115
5.18	INVESTMENT AND FUNDING SCENARIO	116
5.19	IMPACT OF 2025 US TARIFF	117
5.19.1	INTRODUCTION	117
5.19.2	KEY TARIFF RATES	118
5.19.3	PRICE IMPACT ANALYSIS	119
5.19.4	IMPACT ON COUNTRY/REGION	119
5.19.5	IMPACT ON END-USE INDUSTRIES	121
5.20	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	122
6	WEARABLE INJECTORS MARKET, BY PRODUCT	123
6.1	INTRODUCTION	124
6.2	ON-BODY WEARABLE INJECTORS	125
6.2.1	LARGE-VOLUME SUBCUTANEOUS DELIVERY AND HOME-BASED CARE TO DRIVE MARKET	125
6.3	OFF-BODY WEARABLE INJECTORS	128
6.3.1	TECHNOLOGICAL VERSATILITY AND PERSONALIZED DRUG DELIVERY TO DRIVE MARKET	128
7	WEARABLE INJECTORS MARKET, BY DELIVERY METHOD	131
7.1	INTRODUCTION	132
7.2	PROGRAMMED/CONTINUOUS INFUSION	133

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1	NEED FOR PRECISE, CONTROLLED DRUG DELIVERY OVER EXTENDED DURATIONS TO DRIVE SEGMENT	133
7.3	BOLUS-ONLY	135
7.3.1	GROWING DEMAND FOR SELF-ADMINISTERED, SINGLE-DOSE BIOLOGICS TO DRIVE SEGMENT GROWTH	135
8	WEARABLE INJECTORS MARKET, BY END USER	137
8.1	INTRODUCTION	138
8.2	WEARABLE INJECTOR FORMULATION END USERS	138
8.2.1	HOME CARE SETTINGS	141
8.2.1.1	RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET	141
8.2.2	HOSPITALS & CLINICS	143
8.2.2.1	Increased hospital demand for controlled drug delivery boosting market uptake	143
8.2.3	SPECIALTY INFUSION CENTERS/AMBULATORY SURGERY CENTERS	145
8.2.3.1	Cost-efficiency to drive demand for wearable injectors in specialty centers	145
8.2.4	OTHER FORMULATION END USERS	147
8.3	WEARABLE INJECTOR DEVICE END USERS	149
8.3.1	PHARMACEUTICAL COMPANIES	151
8.3.1.1	Need for efficient subcutaneous delivery of large-volume biologics to drive market	151
	?	
8.3.2	BIOTECHNOLOGY COMPANIES	153
8.3.2.1	Improved patient experience, dose accuracy, and at-home administration of complex biologics to drive market	153
8.3.3	CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS	155
8.3.3.1	Innovation through cost-effective and scalable manufacturing solutions to drive market	155
9	WEARABLE INJECTORS MARKET, BY TECHNOLOGY	157
9.1	INTRODUCTION	158
9.2	SPRING-BASED TECHNOLOGY	159
9.2.1	COST-EFFECTIVE ENGINEERING AND MECHANICAL SIMPLICITY TO DRIVE MARKET	159
9.3	MOTOR-DRIVEN TECHNOLOGY	162
9.3.1	PRECISION DOSING AND PROGRAMMABILITY ACCELERATING ADOPTION OF MOTOR-BASED WEARABLE INJECTORS	162
9.4	ROTARY PUMP TECHNOLOGY	164
9.4.1	HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH	164
9.5	EXPANDING BATTERY TECHNOLOGY	166
9.5.1	SHIFT TOWARD HIGH-VOLUME DELIVERY OF VISCOUS DRUGS TO BOOST DEMAND	166
9.6	OTHER TECHNOLOGIES	168
10	WEARABLE INJECTORS MARKET, BY THERAPEUTIC APPLICATION	170
10.1	INTRODUCTION	171
10.2	AUTOIMMUNE DISEASES	172
10.2.1	GROWING PREFERENCE FOR SELF-ADMINISTRATION IN CHRONIC AUTOIMMUNE DISORDERS TO FUEL DEMAND	172
10.3	DIABETES	175
10.3.1	HIGH DISEASE BURDEN AND DAILY INJECTION DEMAND FUEL MARKET DOMINANCE	175
10.4	ONCOLOGY	178
10.4.1	INCREASING NUMBER OF CANCER CASES, SHIFT TOWARD SUBCUTANEOUS CANCER THERAPIES, AND NEED TO REDUCE HOSPITAL BURDEN TO BOOST MARKET	178
10.5	CARDIOVASCULAR DISEASES	180
10.5.1	RISING NEED FOR CONTINUOUS DRUG DELIVERY IN PULMONARY AND CARDIORENAL CONDITIONS TO DRIVE DEMAND	180
10.6	INFECTIOUS DISEASES	182
10.6.1	NEED FOR RAPID AND SELF-ADMINISTERED TREATMENT TO DRIVE ADOPTION	182
10.7	RARE/ORPHAN DISEASES	184
10.7.1	HIGH-COST BIOLOGICS AND PERSONALIZED TREATMENT NEEDS TO DRIVE DEMAND	184

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.8	OTHER THERAPEUTIC APPLICATIONS	186
	?	
11	WEARABLE INJECTORS MARKET, BY USAGE	188
11.1	INTRODUCTION	189
11.2	DISPOSABLE	190
11.2.1	RISING PREFERENCE FOR SIMPLICITY, STERILITY, AND SINGLE-USE SAFETY TO DRIVE DISPOSABLE WEARABLE INJECTORS MARKET	190
11.3	REUSABLE	192
11.3.1	ENABLING LONG-TERM COST EFFICIENCY AND SUSTAINABLE DRUG DELIVERY MODELS TO DRIVE DEMAND	192
12	WEARABLE INJECTORS MARKET, BY REGION	194
12.1	INTRODUCTION	195
12.2	NORTH AMERICA	196
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	197
12.2.2	US	204
12.2.2.1	Growing home healthcare market to drive demand	204
12.2.3	CANADA	209
12.2.3.1	Rising biologic usage and decentralized care pathways to boost demand	209
12.3	EUROPE	213
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	214
12.3.2	GERMANY	220
12.3.2.1	Domestic medtech innovation and government initiatives to fuel growth	220
12.3.3	UK	225
12.3.3.1	NHS digital strategy and homecare shift to accelerate wearable injector adoption	225
12.3.4	FRANCE	230
12.3.4.1	Well-established healthcare system to support market growth	230
12.3.5	ITALY	235
12.3.5.1	Growing demand for cost-effective home care to drive market	235
12.3.6	SPAIN	240
12.3.6.1	Rising prevalence of cancer to drive demand	240
12.3.7	NETHERLANDS	244
12.3.7.1	Strong healthcare infrastructure and aging population to drive market growth	244
12.3.8	REST OF EUROPE	249
12.4	ASIA PACIFIC	254
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	254
12.4.2	CHINA	260
12.4.2.1	Growing investments in healthcare infrastructure to drive market	260
12.4.3	JAPAN	265
12.4.3.1	Large geriatric population to drive demand	265
	?	
12.4.4	INDIA	270
12.4.4.1	Increasing demand for advanced medical treatment to boost market	270
12.4.5	AUSTRALIA	274
12.4.5.1	Rising prevalence of chronic diseases to fuel market	274
12.4.6	THAILAND	279
12.4.6.1	Expansion of universal healthcare to drive growth of wearable injectors market	279
12.4.7	VIETNAM	283
12.4.7.1	Rapidly aging population to drive demand	283

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.4.8	SOUTH KOREA	288
12.4.8.1	Rise of geriatric population to drive growth	288
12.4.9	INDONESIA	292
12.4.9.1	Growing emphasis on home-based care and universal coverage to drive adoption of wearable injectors	292
12.4.10	REST OF ASIA PACIFIC	297
12.5	LATIN AMERICA	301
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	301
12.5.2	BRAZIL	307
12.5.2.1	Increasing number of chronic conditions to drive market	307
12.5.3	MEXICO	312
12.5.3.1	Government initiatives to boost wearable injectors market	312
12.5.4	REST OF LATIN AMERICA	317
12.6	MIDDLE EAST & AFRICA	322
12.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	322
12.6.2	GCC COUNTRIES	327
12.6.2.1	Kingdom of Saudi Arabia (KSA)	332
12.6.2.1.1	Smart healthcare infrastructure and chronic disease burden to propel market expansion	332
12.6.2.2	United Arab Emirates (UAE)	336
12.6.2.2.1	Government support and digital health initiatives to fuel UAE's wearable injectors market	336
12.6.2.3	Rest of GCC Countries	341
12.6.3	REST OF MIDDLE EAST & AFRICA	345
13	COMPETITIVE LANDSCAPE	350
13.1	OVERVIEW	350
13.2	KEY PLAYER STRATEGY/RIGHT TO WIN	350
13.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN WEARABLE INJECTORS MARKET	351
13.3	REVENUE ANALYSIS, 2020?2024	353
13.3.1	WEARABLE INJECTOR DEVICE MANUFACTURERS	353
13.3.2	WEARABLE INJECTOR FORMULATION MANUFACTURERS	353
?		
13.4	MARKET SHARE ANALYSIS	354
13.4.1	WEARABLE INJECTOR DEVICE MANUFACTURERS	354
13.4.2	GLOBAL MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024	355
13.4.3	US MARKET SHARE ANALYSIS OF WEARABLE DEVICE MANUFACTURERS, 2024	356
13.4.4	WEARABLE INJECTOR FORMULATION MANUFACTURERS	357
13.4.5	GLOBAL MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024	358
13.4.6	US MARKET SHARE ANALYSIS OF WEARABLE FORMULATION MANUFACTURERS, 2024	359
13.5	COMPANY EVALUATION MATRIX: DEVICE KEY PLAYERS, 2024	360
13.5.1	STARS	361
13.5.2	EMERGING LEADERS	361
13.5.3	PERVASIVE PLAYERS	361
13.5.4	PARTICIPANTS	361
13.5.5	COMPANY FOOTPRINT: DEVICE KEY PLAYERS, 2024	363
13.5.5.1	Company footprint	363
13.5.5.2	Region footprint	364
13.5.5.3	Product type footprint	364
13.5.5.4	Usage footprint	365
13.5.5.5	Delivery method footprint	365

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.5.5.6	Technology type footprint	366
13.6	COMPANY EVALUATION MATRIX: DEVICE STARTUPS/SMES, 2024	367
13.6.1	PROGRESSIVE COMPANIES	367
13.6.2	DYNAMIC COMPANIES	367
13.6.3	STARTING BLOCKS	367
13.6.4	RESPONSIVE COMPANIES	367
13.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	369
13.6.5.1	Detailed list of key device startups/SME players	369
13.6.5.2	Competitive benchmarking of key SMEs/startups	369
13.7	COMPANY EVALUATION MATRIX: FORMULATION KEY PLAYERS, 2024	370
13.7.1	STARS	370
13.7.2	EMERGING LEADERS	370
13.7.3	PERVASIVE PLAYERS	370
13.7.4	PARTICIPANTS	370
13.7.5	COMPANY FOOTPRINT: FORMULATION KEY PLAYERS, 2024	372
13.7.5.1	Company footprint	372
13.7.5.2	Region footprint	372
13.7.5.3	Product type footprint	373
13.7.5.4	Delivery method footprint	373
13.7.5.5	Therapeutic application footprint	374
13.7.5.6	Technology type footprint	374
13.8	BRAND/PRODUCT COMPARISON	375
13.9	R&D EXPENDITURE OF KEY PLAYERS	376
13.10	COMPANY VALUATION AND FINANCIAL METRICS	376
13.10.1	COMPANY VALUATION	376
13.10.2	FINANCIAL METRICS	377
13.11	COMPETITIVE SCENARIO	377
13.11.1	PRODUCT LAUNCHES & APPROVALS	377
13.11.2	DEALS	378
13.11.3	EXPANSIONS	379
13.11.4	OTHER DEVELOPMENTS	380
14	COMPANY PROFILES	381
14.1	WEARABLE INJECTORS DEVICE MANUFACTURERS	381
14.2	KEY PLAYERS	381
14.2.1	INSULET CORPORATION	381
14.2.1.1	Business overview	381
14.2.1.2	Products/Solutions/Services offered	382
14.2.1.3	Recent developments	383
14.2.1.3.1	Product launches, upgrades, and approvals	383
14.2.1.3.2	Deals	384
14.2.1.3.3	Expansions	384
14.2.1.4	MnM view	385
14.2.1.4.1	Key strengths	385
14.2.1.4.2	Strategic choices	385
14.2.1.4.3	Weaknesses & competitive threats	385
14.2.2	TANDEM DIABETES CARE, INC.	386
14.2.2.1	Business overview	386

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.2.2.2	Products/Solutions/Services offered	387
14.2.2.3	Recent developments	388
14.2.2.3.1	Product launches, upgrades, and approvals	388
14.2.2.3.2	Deals	389
14.2.2.4	MnM view	390
14.2.2.4.1	Key strengths	390
14.2.2.4.2	Strategic choices	390
14.2.2.4.3	Weaknesses & competitive threats	390
14.2.3	MEDTRONIC	391
14.2.3.1	Business overview	391
14.2.3.2	Products/Solutions/Services offered	392
14.2.3.3	Recent developments	393
14.2.3.3.1	Product launches, upgrades, and approvals	393
14.2.3.3.2	Deals	393
?		
14.2.3.4	MnM view	394
14.2.3.4.1	Key strengths	394
14.2.3.4.2	Strategic choices	394
14.2.3.4.3	Weaknesses & competitive threats	394
14.2.4	BD	395
14.2.4.1	Business overview	395
14.2.4.2	Products/Solutions/Services offered	396
14.2.4.3	Recent developments	397
14.2.4.3.1	Deals	397
14.2.4.3.2	Expansions	397
14.2.4.3.3	Other developments	398
14.2.4.4	MnM view	398
14.2.4.4.1	Key strengths	398
14.2.4.4.2	Strategic choices	398
14.2.4.4.3	Weaknesses & competitive threats	398
14.2.5	WEST PHARMACEUTICAL SERVICES, INC.	399
14.2.5.1	Business overview	399
14.2.5.2	Products/Solutions/Services offered	400
14.2.5.3	Recent developments	401
14.2.5.3.1	Expansions	401
14.2.5.4	MnM view	402
14.2.5.4.1	Key strengths	402
14.2.5.4.2	Strategic choices	402
14.2.5.4.3	Weaknesses & competitive threats	402
14.2.6	GERRESHEIMER AG	403
14.2.6.1	Business overview	403
14.2.6.2	Products/Solutions/Services offered	404
14.2.6.3	Recent developments	405
14.2.6.3.1	Expansions	405
14.2.7	STEVANATO	406
14.2.7.1	Business overview	406
14.2.7.2	Products/Solutions/Services offered	407

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2.7.3 Recent developments 408
- 14.2.7.3.1 Product launches, upgrades, and approvals 408
- 14.2.7.3.2 Deals 408
- 14.2.8 LTS LOHMANN THERAPIE-SYSTEME AG 409
- 14.2.8.1 Business overview 409
- 14.2.8.2 Products/Solutions/Services offered 409
- 14.2.8.3 Recent developments 410
- 14.2.8.3.1 Product launches, upgrades, and approvals 410
- 14.2.8.3.2 Deals 410
- 14.2.8.3.3 Expansions 411
- 14.2.9 SONCEBOZ 412
- 14.2.9.1 Business overview 412
- 14.2.9.2 Products/Solutions/Services offered 412
- 14.2.10 NEMERA 413
- 14.2.10.1 Business overview 413
- 14.2.10.2 Products/Solutions/Services offered 413
- 14.2.10.3 Recent developments 414
- 14.2.10.3.1 Deals 414
- 14.2.10.3.2 Expansions 414
- 14.2.11 MANNKIND CORPORATION 415
- 14.2.11.1 Business overview 415
- 14.2.11.2 Products/Solutions/Services offered 416
- 14.2.11.3 Recent developments 416
- 14.2.11.3.1 Deals 416
- 14.2.12 ENABLE INJECTIONS, INC. 417
- 14.2.12.1 Business overview 417
- 14.2.12.2 Products/Solutions/Services offered 417
- 14.2.12.3 Recent developments 418
- 14.2.12.3.1 Product launches, upgrades, and approvals 418
- 14.2.12.3.2 Deals 418
- 14.2.12.3.3 Expansions 419
- 14.2.12.3.4 Other developments 419
- 14.2.13 ELCAM MEDICAL 420
- 14.2.13.1 Business overview 420
- 14.2.13.2 Products/Solutions/Services offered 420
- 14.2.13.3 Recent developments 421
- 14.2.13.3.1 Expansions 421
- 14.3 OTHER PLAYERS 422
- 14.3.1 DEBIOTECH SA 422
- 14.3.2 MEDTRUM TECHNOLOGIES INC. 423
- 14.3.3 CEQR SIMPLICITY 424
- 14.3.4 SUBCUJECT APS 425
- 14.3.5 MICROMED CO., LTD 425
- 14.4 WEARABLE INJECTORS WITH FORMULATION MANUFACTURERS 426
- 14.4.1 AMGEN INC. 426
- 14.4.1.1 Business overview 426
- 14.4.1.2 Products/Solutions/Services offered 427

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.4.1.3	Recent developments	427
14.4.1.3.1	Deals	427
14.4.1.3.2	Expansions	428
	?	
14.4.2	ABBVIE INC.	429
14.4.2.1	Business overview	429
14.4.2.2	Products/Solutions/Services offered	430
14.4.2.3	Recent developments	431
14.4.2.3.1	Product launches, upgrades, and approvals	431
14.4.2.3.2	Expansions	432
14.4.3	UNITED THERAPEUTICS CORPORATION	433
14.4.3.1	Business overview	433
14.4.3.2	Products/Solutions/Services offered	434
14.4.3.3	Recent developments	434
14.4.3.3.1	Expansions	434
14.4.4	APELLIS PHARMACEUTICALS, INC.	435
14.4.4.1	Business overview	435
14.4.4.2	Products/Solutions/Services offered	436
14.4.4.3	Recent developments	436
14.4.4.3.1	Product launches, upgrades, and approvals	436
14.4.5	SUPERNUS PHARMACEUTICALS	437
14.4.5.1	Business overview	437
14.4.5.2	Products/Solutions/Services offered	438
14.4.5.3	Recent developments	438
14.4.5.3.1	Product launches, upgrades, and approvals	438
14.4.6	COHERUS BIOSCIENCES, INC.	439
14.4.6.1	Business overview	439
14.4.6.2	Products/Solutions/Services offered	440
14.4.6.3	Recent developments	440
14.4.6.3.1	Product launches, upgrades, and approvals	440
14.4.6.3.2	Other developments	440
14.4.7	SCPHARMACEUTICALS, INC.	441
14.4.7.1	Business overview	441
14.4.7.2	Products/Solutions/Services offered	442
14.4.7.3	Recent developments	442
14.4.7.3.1	Product launches, upgrades and approvals	442
15	APPENDIX	443
15.1	DISCUSSION GUIDE	443
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	448
15.3	CUSTOMIZATION OPTIONS	450
15.4	RELATED REPORTS	450
15.5	AUTHOR DETAILS	451

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Wearable Injectors Market by Product (On-body, Off-body), Technology (Spring, Motor Driven, Rotary Pump), Usage (Disposable, Reusable), Delivery Method (Bolus, Programmed Infusion), Therapeutic Application (Diabetes, Oncology), End User - Forecast to 2030

Market Report | 2025-09-09 | 452 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-17

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com